How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD

This video interview features Steven Nissen, MD, telling his 2007 story of revealing that the number-1 diabetes drug, rosiglitazone, led to more cardiovascular events than placebo or a variety of competitors. The discovery resulted in new requirements for clinical trials to rule out harm. It focuses...

Full description

Saved in:
Bibliographic Details
Published inMethodist DeBakey cardiovascular journal Vol. 18; no. 5; pp. 54 - 57
Main Authors Nissen, Steven E, Young, James B
Format Journal Article
LanguageEnglish
Published United States Houston Methodist DeBakey Heart & Vascular Center 2022
Subjects
Humans
Hypoglycemic Agents - adverse effects
Interview
Rosiglitazone - adverse effects
United States
United States
US Food and Drug Administration (FDA) drug approval
drug development
clinical trials
Online AccessGet full text

Cover

More Information
Summary:This video interview features Steven Nissen, MD, telling his 2007 story of revealing that the number-1 diabetes drug, rosiglitazone, led to more cardiovascular events than placebo or a variety of competitors. The discovery resulted in new requirements for clinical trials to rule out harm. It focuses on how a new understanding of drug or drug class pharmacology often drives drug development, and includes a discussion of the approval process, which may bring a different result than was originally intended. View the video at https://youtu.be/aFtCfZyd54E.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1947-6108
1947-6094
1947-6108
DOI:10.14797/mdcvj.1181